Sirius Analytical are seeking partners with access to compound and formulation information that can be used for further validation of the instrument that mimics the subcutaneous environment of the human body.
OcuScience are looking to work with collaborators who have expertise in various diseases of the retina to provide direction and validation of the human disease models detailed in this Solution.
Partners are sought to help further develop and validate the spinal cord slice preparations for studying nociception and neuroinflammation ex vivo, and for preclinical development of novel therapeutics.
Immundnz Ltd are seeking partnerships with companies to help validate COMPIT in an industrial setting. COMPIT is an in vitro platform that enables the comprehensive analysis and prediction of the human immune response to drug molecules.
Partners are sought to develop and expand the experimental cancer medicine platforms across various cancer types, and validate the platform for preclinical drug development.
This quantitative cell-based neurotoxin assay would be suitable for both tetanus and botulinum product development and partners are sought to help validate the assay using toxoid samples.
Partners interested in applying the technology to a wide variety of applications are sought to assess the utility of the optical coherence tomography, which enables qualitative and quantitative characterisation of tissue structure and function in vivo.
Stemina is seeking partners to help expand the use of their assays, devTOX quickPredict and devTOX Discovery, for human developmental toxicity screening.
Partners are sought to explore the application of these microfluidic devices in an industrial setting to assess efficacy and safety of drugs.
Partners are sought to explore the integration of TruLarv™, research-grade G. mellonella larvae, into drug screening platforms.
Partners are sought with the expertise and facilities to carry out in vitro toxicity tests with cultured mammalian cells, to validate the researchers toxicokinetic and toxicodynamic model.
Lena Biosciences is seeking collaborators to validate, manufacture and commercialise their 3D cell culture perfusion platform which enables testing of slow-clearing biologicals and drugs.
Partners are sought to help develop and test this novel mass spectrometry-based profiling method that can detect the binding of unmodified chemicals to potentially thousands of targets expressed in cell microarrays.
Somark Innovations is seeking partners to adopt and evaluate their Labstamp mouse identification system.
Data Sciences International is seeking partners to adopt their implantable telemetry device capable of providing continuous, real-time measurements of blood glucose, temperature, and activity in rats.
Avacta Life Sciences are seeking partners to help in the validation and development of Affimers, animal-free alternatives to antibodies.